BlueSphere Bio

BlueSphere Bio

  • Founded: 2017
  • Location: Pittsburgh , PA
  • Employee range: 1 - 10
  • Clinical stage: Clin0
  • Therapy area: Multiple cancers
  • Drug types: ONC
  • Lead product: TCX-101 platform
  • Product link:
  • Funding: $10M A late 2018

job board

Short description:

T Cell Therapy

Drug notes:

Also RD oncology; TCX-201 2 efforts RD solid tumors

Long description:

BlueSphere Bio is personalizing T-cell therapies for the treatment of cancer. As every cancer is unique, BlueSphere believes so should therapies. BlueSphere is enabling each patient’s immune system to provide the ability to create their own personal adoptive cell therapy (ACT) to treat their cancer. To achieve this, BlueSphere is using their proprietary technology to harness the specificity of each patient’s T cells for the unique molecular fingerprint of their own cancer. Combined, the technologies screen tumor-resident T cell receptors (TCR) for reactivity to identified neoantigens and create libraries of TCRs and neoantigens to select the best match for ACT. BlueSphere’s lead program, TCX-101, is being tested as a curative therapy for patients with hematologic malignancies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy